Efficacy of Salidroside in treating postmenopausal osteoporosis in rats and analysis of glutathione peroxidase 4 expression
BI Wen-xiu,WANG Peng,TIAN Ai-xian
Abstract:
Objective To investigate the bone-protective effects of Salidroside on postmenopausal osteoporosis model rats and its influence on glutathione peroxidase 4 (GPX4) expression. Methods A total of 18 female SD rats were randomly divided into three groups, with six rats in each group. The groups were the sham-operated group, the model group, and the Salidroside group. The sham surgery group underwent sham operation, while the model group underwent bilateral ovariectomy to establish a postmenopausal osteoporosis rat model. Salidroside group: After successful modeling, rats were administered Salidroside solution (40 mg/kg) via intraperitoneal injection, while the model group received an equal volume of physiological saline via intraperitoneal injection, once daily for two months. Subsequently, rats underwent DXA testing, serum samples were collected for ELISA testing, and femoral bone tissue was harvested for Micro-CT, Western blot, qRT-PCR, and immunohistochemical analysis. Results DXA results showed that compared with the sham-operated group, BMD in the model group was significantly reduced, confirming the success of the model. After drug administration, BMD in the Salidroside group was significantly higher than that in the model group (P <0.01). Micro-CT results showed that the red ginseng glycoside group had significantly higher BV/TV, Tb.Th, and Tb.N compared to the model group, while Tb.Sp was significantly lower (P <0.05). ELISA results indicated that compared with the sham-operated group, serum osteocalcin (OC) and type I procollagen N-terminal propeptide (PINP) levels were significantly reduced in the model group, while type I collagen C-terminal propeptide (β-CTX) levels were significantly increased, and 4-hydroxy-2-nonenal (4-HNE) levels were significantly elevated. The Salidroside group showed significantly higher levels of OC and PINP compared to the model group, while β-CTX and 4-HNE expression levels were significantly lower (P <0.01). qRT-PCR and Western blot analysis showed that GPX4 expression levels were reduced in the model group, while the Salidroside group exhibited significantly higher GPX4 expression levels compared to the model group. Immunohistochemistry showed that compared with the sham-operated group, the GPX4 protein expression levels in the model group were significantly reduced, while those in the Salidroside group were significantly increased compared with the model group (P <0.01). Conclusion Salidroside inhibits the ferroptosis process by regulating the expression levels of GPX4, effectively treating postmenopausal osteoporosis in rats, increasing bone mass, and improving their osteoporosis condition.
